The metabolic adverse effects of antipsychotic use in individuals with intellectual and/or developmental disability: A systematic review and meta-analysis.
antipsychotic agents
autism spectrum disorder
intellectual disability
metabolic side effects of drugs and substances
weight gain
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
20
07
2022
received:
01
04
2022
accepted:
21
07
2022
pubmed:
28
7
2022
medline:
16
8
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
Individuals with intellectual and/or developmental disability (IDD) are often prescribed antipsychotics (APs). However, despite their known propensity to cause metabolic adverse effects, including weight gain, diabetes, and increased risk of cardiovascular events, there is currently a limited body of literature describing the metabolic consequences of AP use in this population. We searched MEDLINE, EMBASE, PsychINFO, CENTRAL, and CINAHL databases to identify all randomized trials that reported on the metabolic effects of APs in individuals with IDD. Random effects meta-analyses were used to examine weight gain as both a continuous and dichotomous outcome. Eighteen randomized trials met our inclusion criteria with a total of 1376 patients across a variety of IDDs. AP use was associated with significantly greater weight gain compared with placebo (Continuous: mean difference = 1.10 kg, [0.79, 1.40], p < 0.00001, I This review (PROSPERO # CRD42021255558) demonstrates that AP use is associated with significant weight gain among patients with IDD. Concerningly, most reported studies were in children and adolescents, which sets up an already vulnerable population for adverse medical sequalae at an early age. There was also a lack of long-term studies in adults with IDD. Further studies are required to better understand how AP use affects metabolic parameters in this group of individuals.
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-214Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lunsky Y, Balogh R, Cobigo V, Isaacs B, Lin E, Ouellette-Kuntz H. Primary care of adults with developmental disabilities in Ontario. Healthc Q. 2014;17(3):11-13.
Lunsky Y, Khuu W, Tadrous M, Vigod S, Cobigo V, Gomes T. Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities: utilisation d'antipsychotiques chez les adultes présentant une déficience intellectuelle et avec ou sans diagnostic psychiatri. Can J Psychiatry. 2018;63(6):361-369.
Esler A, Hewitt A, Hall-Lande J, Pettingell SL, Houseworth J. Psychotropic medication use for adults with autism spectrum disorder who receive services and supports through adult developmental disability services in the United States. J Autism Dev Disord. 2019;49(6):2291-2303.
Gomes T, Khuu W, Tadrous M, Vigod S, Cobigo V, Lunsky Y. Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. BMJ Open. 2019;9(7):e028125.
Robertson J, Emerson E, Gregory N, Hatton C, Kessissoglou S, Hallam A. Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellect Disabil Res. 2000;44(6):666-676.
Tsiouris JA, Kim S-Y, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord. 2013;43(3):719-731.
Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015;351:h4326.
Perry BI, Cooray SE, Mendis J, et al. Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey. J Intellect Disabil Res. 2018;62(2):140-149.
McLaren JL, Lichtenstein JD, Metcalfe JD, Charlot LR, Drake RE, Beasley JB. Psychotropic use among youths with intellectual and developmental disabilities. Psychiatr Serv. 2021;72:988-997.
Brophy S, Kennedy J, Fernandez-Gutierrez F, et al. Characteristics of children prescribed antipsychotics: analysis of routinely collected data. J Child Adolesc Psychopharmacol. 2018;28(3):180-191.
Warren Z, Veenstra-VanderWeele J, Stone W, et al. AHRQ comparative effectiveness reviews. Therapies for Children with Autism Spectrum Disorders. Agency for Healthcare Research and Quality (US); 2011.
McLaren JL, Barnett ER, Concepcion Zayas MT, et al. Psychotropic medications for highly vulnerable children. Expert Opin Pharmacother. 2018;19(6):547-560.
Stogios N, Bowden S, Tran V, et al. Weight gain and metabolic adverse effects of off-label second-generation antipsychotic use in the adult population: a systematic review and meta-analysis. Biol Psychiatry. 2021;89(9):S344.
Vancampfort D, Schuch F, Van Damme T, et al. Metabolic syndrome and its components in people with intellectual disability: a meta-analysis. J Intellect Disabil Res. 2020;64(10):804-815.
Florio T, Trollor J. Mortality among a cohort of persons with an intellectual disability in New South Wales. Australia J Appl Res Intellect Disabil. 2015;28(5):383-393.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons; 2018.
Schünemann HJ, Higgins JPT, Vist GE, et al. Chapter 14: completing ‘summary of findings’ tables and grading the certainty of the evidence. In: JPT H SG, ed. Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022). John Wiley & Sons; 2022.
DeVane CL, Charles JM, Abramson RK, et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy. 2019;39(6):626-635.
Amore M, Bertelli M, Villani D, Tamborini S, Rossi M. Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. J Intellect Disabil Res. 2011;55(2):210-218.
Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008;17(1):1-8.
McDougle CJ, Holmes JP, Carlson C, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55(7):633-641.
Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346.
Kent JM, Kushner S, Ning X, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43(8):1773-1783.
Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575-587.
McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. New Engl J Med. 2002;347(5):314-321.
Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450-455.
Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634-e641.
Buitelaar JK, van der Gaag RJ, Melman CTM. Risperidone in the treatment of aggressive behaviour disorders in adolescents with mild mental retardation. A prospective, randomised, double-blind, placebo-controlled trial. Conference Abstract; 1998.
Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026-1036.
Ichikawa H, Mikami K, Okada T, et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry Hum Dev. 2017;48(5):796-806.
Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119.
Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540.
Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541-548.
Loebel A, Brams M, Goldman RS, et al. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord. 2016;46(4):1153-1163.
Singh NN, Aman MG. Effects of thioridazine dosage on the behavior of severely mentally retarded persons. Am J Ment Defic. 1981;85(6):580-587.
Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239-248.
Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73-96.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126.
Hayden JD, Horter L, Parsons T III, et al. Metabolic monitoring rates of youth treated with second-generation antipsychotics in usual care: results of a Large US National Commercial Health Plan. J Child Adolesc Psychopharmacol. 2020;30(2):119-122.
Dhamane AD, Martin BC, Brixner DI, Hudson TJ, Said Q. Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract. 2013;19(5):360-374.
Coughlin M, Goldie CL, Tregunno D, Tranmer J, Kanellos-Sutton M, Khalid-Khan S. Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics. Int J Ment Health Nurs. 2018;27(3):1188-1198.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93.
Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig. 2015;12(2):242-248.
Iasevoli F, Barone A, Buonaguro EF, Vellucci L, de Bartolomeis A. Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opin Drug Saf. 2020;19(11):1419-1444.
Sheehan R, Hassiotis A. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Lancet Psychiatry. 2017;4(3):238-256.
Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295-314.
Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17(2):97-103.
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112.
Galling B, Roldán A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiat. 2016;73(3):247-259.
Rajkumar AP, Horsdal HT, Wimberley T, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174(7):686-694.
Martín A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry. 2004;161(6):1125-1127.
Bazo-Alvarez JC, Morris TP, Carpenter JR, Hayes JF, Petersen I. Effects of long-term antipsychotics treatment on body weight: a population-based cohort study. J Psychopharmacol. 2020;34(1):79-85.
Zullino D, Bilancioni R, Conus P, Schwartz B, Khazaal Y, Baumann P. Off-label utilization of antipsychotics. S Afr Psychiatr Rev. 2006;9:38-43.
Castellani LN, Costa-Dookhan KA, McIntyre WB, et al. Preclinical and clinical sex differences in antipsychotic-induced metabolic disturbances: a narrative review of adiposity and glucose metabolism. J Psychiatr Brain Sci. 2019;4:e190013.
Liu J, Hanley AJG, Young TK, Harris SB, Zinman B. Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada. Int J Obes (Lond). 2006;30(4):669-676.
Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health. 2007;7(1):220.
Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
Lunsky Y, Modi M. Predictors of psychotropic polypharmacy among outpatients with psychiatric disorders and intellectual disability. Psychiatr Serv. 2018;69(2):242-246.